Amgen plans to embed AI across R&D and operations, focusing on pipeline acceleration and manufacturing productivity, with a total capital expenditure of approximately $2.6 billion in 2026 to support these initiatives.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
How is Amgen planning to allocate its AI-related spending and capital expenditures in R&D and operations for 2026?
From Amgen’s 2026 outlook discussion, the company is embedding AI/data science into both R&D and operations, but it does not provide a numeric budget specifically labeled “AI spending” for 2026 in the excerpts provided. Instead, Amgen signals AI investment through (1) higher non-GAAP R&D spending year over year tied to late-stage pipeline investments and AI-enabled drug discovery/development work, and (2) forecasted total capital expenditures for 2026 used to scale manufacturing capacity (including for Meritide), while also describing measurable AI-driven operational productivity improvements on manufacturing lines. 123
Amgen frames its AI/data science efforts as integrated across R&D—citing examples such as:
However, the excerpted materials do not translate these AI initiatives into a separate “AI R&D spend” number for 2026. 2
In the Q1 2026 commentary, Amgen states it increased non-GAAP R&D spending by 16% year over year in the first quarter, attributing the increase to continued investments in late stage assets including Meritide, IMBELTRA, and opasiran. 3
While this is not explicitly “AI spending,” it indicates that Amgen’s overall R&D allocation for 2026 is geared toward advancing late-stage programs—the same period where Amgen’s described AI capabilities are being used to improve discovery, clinical execution, and regulatory preparation. 23
What this implies about allocation: AI-related work is being absorbed into broader R&D and pipeline execution spending, rather than separated out as a distinct line item in the excerpt. 23
Amgen provides a concrete operational example of AI-enabled automation: it reduced production line clearance time at one manufacturing site from ~30 minutes to ~2 minutes per batch run. 1
It also notes “promising results” as colleagues use AI to enhance productivity across Amgen. 1
Again, the excerpts do not quantify the AI operations budget; rather, they describe operational outcomes that would typically be associated with technology enablement investments. 1
Amgen reports it spent $700 million in capex in the first quarter, driven by investments across U.S. manufacturing sites including Ohio, North Carolina, and Puerto Rico. 3
For full-year 2026, Amgen expects capital expenditures of approximately $2.6 billion, describing this as significant investment to scale manufacturing capacity for volume growth, including Meritide’s launch. 3
Therefore, allocation in operations is primarily capex-driven toward manufacturing scale, while AI-enabled automation is presented as improving manufacturing throughput and productivity within those operations. 13
R&D allocation (AI-enabled work embedded in pipeline investment):
Amgen is increasing R&D investment (non-GAAP R&D up 16% year over year in Q1, tied to late-stage investments including Meritide, IMBELTRA, and opasiran), while also stating that AI and data science are producing tangible improvements across R&D processes (e.g., 50% faster antibody lead optimization, improved clinical enrollment via a proprietary site-selection model, and use of agentic AI for regulatory document preparation). 23
Operations allocation (AI improves productivity; capex funds manufacturing scale):
Amgen’s AI-related operational approach is reflected in measurable manufacturing productivity gains (clearance time reduced to about two minutes from approximately 30 minutes), while its 2026 capital expenditures are guided at ~$2.6 billion**, primarily to scale U.S. manufacturing capacity for volume growth (including Meritide’s launch). 13
Budget structure (no standalone AI spending numbers provided):
In the excerpts provided, Amgen does not disclose a separate 2026 budget line-item solely for AI spending; instead, AI is presented as being integrated into broader R&D execution and supported by capex aimed at manufacturing scaling, with AI’s effect demonstrated through productivity and process improvements. 123
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Amgen explains MariTide’s long-acting dosing profile and the shift toward monthly initiation with transitions to less frequent maintenance schedules. The discussion covers a Phase III escalation plan to reach target dosing in 2 months and ongoing maintenance options that may reduce injections per year.
Sources used
Research questionWhat did management say about MariTide dosing duration and schedules?
Answer outline
Amgen lays out two distinct Phase III programs for dazodalibep in Sjögren’s disease, one targeting systemic manifestations and the other symptomatic burden, each with tailored endpoints. The company highlights unmet patient need, cites differences in measurement tools (ESSDAI vs ESSPRI and diary-based PROs), and projects learning more in H2 with enrollment of 621 systemic and 434 symptomatic participants.
Sources used
Research questionWhat did management say about Dazodalibep systemic vs symptomatic trials?
Answer outline
Amgen's 2026 growth strategy centers on advancing its pipeline, particularly Meritide, while expanding oncology offerings and scaling manufacturing capacity. The company leverages AI and data science to enhance R&D and operational efficiency, with a focus on delivering long-term shareholder value.
Sources used
Research questionWhat are Amgen's key focus areas in its pipeline and long-term growth strategies for 2026?
Answer outline
Amgen’s MariTide, an antibody-peptide conjugate, is designed to preserve GLP-1 agonism and GIP antagonism across the antibody-driven half-life, supporting less frequent maintenance dosing from monthly to as few as 4–6 doses per year. Real-world dosing will hinge on physician guidance and patient experience, with flexibility but no reliable prediction of patient-led interval selection.
Sources used
Research questionThanks for all the details today and all the commentary on the pipeline. So my question is for Jay, please. Regarding MariTide's construct, so it's GLP-1 peptides conjugated to a GIP antagonist antibody, of course. Could you discuss the duration of effect of each mechanism and potential implications for duration of efficacy, obviously, since the peptide component will last a lot shorter than the antibody. And then if you could also comment on whether you expect real-world patient-led dosing selection for every 1, 2 or 3 months maintenance dosing based upon individual experience. Is that the right way that we should be thinking about it?
Answer outline
Cintas management described cross-selling as a broad, customer-specific opportunity rather than one centered on a single product line. Representatives can identify needs through regular customer relationships and help Cintas capture spending customers already direct to other providers. The effort is progressing incrementally, including across rental and First Aid and Safety, and management sees it as a potential ongoing contributor.
Sources used
Research questionWhat did management say about Broad-based cross-selling opportunity?
Oracle said its global data center buildout is advancing across multiple markets, with 850 megawatts of AI capacity delivered in Q1 and record new capacity brought online. Abilene has made substantial progress, while projects in Shackleford, New Mexico, and Wisconsin continue on differing timelines. Management is planning for phased delivery and execution risks, and said New Mexico and Wisconsin will not change FY2027 guidance.
Sources used
Research questionWhat did management say about Global data center expansion status?
Answer outline
Cencora explains that value-based discussions with manufacturers rely on the total economic value of its platform—technology, automation, secure handling, and analytics—rather than a simple logistics fee, enabling sustained profitability even as pricing pressures rise.
Sources used
Research questionWhat did management say about Value discussions with manufacturers?
Answer outline
In Q3 FY2026, ADI's management signals a resilient capacity position centered on hybrid manufacturing, with ongoing internal expansion, external wafer sourcing, and inventory build. They note industry lead times are lengthening but actively mitigated through demand visibility and multi-node planning with external partners.
Sources used
Research questionWhat did management say about Capacity planning and supply constraints?
Answer outline
Starbucks outlines a Back to Starbucks strategy prioritizing winning the morning daypart as the core growth engine, with execution anchored in staffing, deployment, and a superior morning customer experience across channels. Management expects afternoon gains to follow as beverage/food mix, routines, and digital menu boards roll out widely, extending momentum through the day.
Sources used
Research questionWhat did management say about Daypart strategy: morning win?
Answer outline
Starbucks management frames the Uplifts program as creating a positive halo across stores, lifting transactions and boosting brand health to five-year highs while not disrupting customer routines. With an average investment of about $150,000 per site, the program has already surpassed 1,000 uplifts in North America and will accelerate the rollout to reach 1,500 by year-end 2026 and beyond in fiscal 2027.
Sources used
Research questionWhat did management say about Uplifts program impact on stores?
Answer outline
US Foods outlines an ongoing AI productivity program that reinvests efficiency gains into the business and expands AI/data science capabilities, framing AI as part of the existing reinvestment framework rather than a standalone lever. Management links AI to near-term improvements in sales productivity and supply-chain tools, maintains a mid-single-digit headcount growth plan for 2026, and notes an 8% seller headcount rise in Q2 to pre-empt turnover and position for a steadier second half of 2026.
Sources used
Research questionWhat did management say about AI productivity reinvestment and hiring plans?
Answer outline
Management outlined a phased Biocarbon expansion, prioritizing the first McComb-area facility and detailing the groundwork, permitting, and testing required before construction can begin. They expect additional site announcements later this year or early next year, with subsequent deployments likely easier once initial groundwork is in place, guided by supply chains, logistics, and market conditions.
Sources used
Research questionWhat did management say about Biocarbon site expansion timeline?
Answer outline
Dafinchi